Theriva Biologics, Inc. · AMEX:TOVX

Theriva Biologics — Investor Presentation (December 2024)

42 slides from Theriva Biologics's investor presentation, December 2024

  1. Slide 1: Corporate Overview December 2024

    Corporate Overview December 2024

  2. Slide 2: Forward Looking Statements

    FORWARD LOOKING STATEMENTS This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward- looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "antici

  3. Slide 3: Overview

    OVERVIEW • Theriva Biologics is developing unique oncolytic viruses optimized for systemic administration Financial Snapshot Exchange NYSE American • VCN-01 is undergoing a Phase 2b clinical trial in Ticker TOVX first-line metastatic pancreatic cancer in Cash (09/30/2024) $16.4M combination with SoC

  4. Slide 4: Seasoned Leadership Team

    SEASONED LEADERSHIP TEAM Steven Shallcross Manel Cascalló PhD Vince Wacher PhD Chief Executive Officer, Chief Financial General Director, EU Subsidiary Head Corporate Development Officer Expertise in oncolytic adenovirus clinical Nearly 30 years leading corporate strategy, Served as the Company’s CE

  5. Slide 5: Theriva Pipeline

    THERIVA PIPELINE Candidate Target Pre-IND Phase 1 Phase 2 Phase 3 Collaborators Status* Phase 2b Study On-going Pancreatic Cancer (IV) with Orphan Drug Designation US, EU gemcitabine/nab-paclitaxel Fast Track Designation US Phase 1 Complete, CSR in preparation Retinoblastoma (IVit) Orphan Drug Desig

  6. Slide 6: VCN-01 Is a Uniquely Engineered Human Adenovirus

    VCN-01 IS A UNIQUELY ENGINEERED HUMAN ADENOVIRUS 5 Access primary and metastatic lesions Systemic High dose, highly replicating Replicates only in tumor cells Selective Liver detargeted Expresses PH20 (hyaluronidase) Stroma Degrading after viral replication cycle -- RGDK PH20 in blood is a potential

  7. Slide 7: VCN-01 Is a Uniquely Engineered Human Adenovirus

    VCN-01 IS A UNIQUELY ENGINEERED HUMAN ADENOVIRUS 5 SYSTEMIC administration enables VCN-01 access to SELECTIVE replication at very high levels lyses tumor 1 primary tumor and metastases and detargets the liver 2 cells directly without harming healthy tissues VCN-01 Tumor Surrounded by STROMA Cancer A

  8. Slide 8: VCN-01 Designed to Have Multiple Anti-Tumor Actions

    VCN-01 DESIGNED TO HAVE MULTIPLE ANTI-TUMOR ACTIONS STROMA degradation by PH20 facilitates tumor access IMMUNOGENIC actions of VCN-01 turn “cold” tumors 3 and destruction by coadministered cancer therapies 4 “hot” and elicit an anti-tumor immune response PH20 nab-paclitaxel PH20 PH20 PH20 gemcitabin

  9. Slide 9: VCN-01 Compared to Other Oncolytic Viruses in Development

    VCN-01 COMPARED TO OTHER ONCOLYTIC VIRUSES IN DEVELOPMENT THERIVA ONCOLYTICS COMPANY CG ONCOLOGY GENELUX REPLIMMUNE BIOLOGICS BIOTECH Ticker NYSE MKT: TOVX NASDAQ: CGON NASDAQ: GNLX NASDAQ:ONCY NASDAQ: REPL Market Cap¹ $3.5M $2.3B $86M $74M $984M Product VCN-01 CG0070 Olvi-Vec Pelareorep RP1, RP2 Vi

  10. Slide 10: VCN-01 Extensive Clinical Program

    VCN-01 EXTENSIVE CLINICAL PROGRAM 142 patients treated with VCN-01 to date in multiple indications and combinations Rb – IVit BRAIN TUMORS – IV (1)* alone (9) COLORECTAL – IV Alone (15) HEAD & NECK – IV alone (1) HEAD & NECK – IV PANCREATIC - IV + Durvalumab (20) + Gemcitabine / Abraxane® Phase 1 (2

  11. Slide 11: VCN-01 Lead Indication Pancreatic Cancer

    VCN-01 LEAD INDICATION PANCREATIC CANCER Highly fatal cancer protected by dense tumor stroma • Orphan disease with the highest mortality of all solid tumors • Median survival 8-11 months for metastatic disease1,2 • USA est. 66,440 new cases and 51,750 deaths in 20243 • Hyaluronic acid in stroma is a

  12. Slide 12: VCN-01 Dose Regimen Established in Phase 1

    VCN-01 DOSE REGIMEN ESTABLISHED IN PHASE 1 Multicenter, open-label, dose escalation study (NCT02045602) ✓ Single IV doses of VCN-01 alone or with standard-of-care (SoC) chemotherapy gemcitabine/nab-paclitaxel (Abraxane®) ✓ Evaluate safety and tolerability, recommended Phase 2 dose ¹Single dose of VC

  13. Slide 13: VCN-01 Favorable Outcomes in Phase 1 Trial

    VCN-01 FAVORABLE OUTCOMES IN PHASE 1 TRIAL Multicenter, open-label, dose escalation study (NCT02045602) OUTCOME VCN-01 DOSE, virus particles (n)¹ SoC ALONE² RELATED AEs IN ≥1 PATIENT¹ CTCAE SEVERITY Sequential Regimen 3.3x10¹² (6) 1.0x10¹³ (6) Combined (12) Phase 3 (431) VCN-01 Combined, Sequential

  14. Slide 14: Clinical Data Support VCN-01 Mode-of-Action

    CLINICAL DATA SUPPORT VCN-01 MODE-OF-ACTION Remodels the tumor matrix and turns “cold” tumors “hot” Persistent replication: PH20 levels in patient sera Immune markers upregulated in indicate sustained VCN-01 activity in tumors biopsies of hepatic metastases VCN-01 1.0x10¹³ vp (Arms I, II, III) CD8+

  15. Slide 15: VIRAGE Phase 2b Clinical Trial in Pancreatic Cancer

    VIRAGE PHASE 2B CLINICAL TRIAL in PANCREATIC CANCER Multicenter, open-label, randomized, controlled trial (NCT05673811) • Evaluating first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC) • Randomized 1:1 to receive gemcitabine/nab-paclitaxel SoC or up to two doses

  16. Slide 16: VIRAGE Phase 2 Clinical Trial Differentiators

    VIRAGE PHASE 2 CLINICAL TRIAL DIFFERENTIATORS ✓ First-line treatment provides best opportunity to observe potential effect ✓ Direct comparison with SoC chemotherapy is the most rigorous control ✓ Repeated dosing of VCN-01 may improve treatment outcomes ✓ Open label provides real-time opportunity to

  17. Slide 17: Achievements and Projected Milestones

    ACHIEVEMENTS AND PROJECTED MILESTONES • VCN-01 PDAC • VCN-01 PDAC • VCN-01 PDAC • VCN-01 PDAC • Ph2 enrollment achieved ✓ • Type D meeting with FDA ✓ • EMA Scientific Advice • Initiate Phase 3 trial • Spanish Government Public- potential pivotal trial design potential pivotal trial design if regulat

  18. Slide 18: VCN-01 in Head & Neck Cancer

    @ Theriva VCN-01 IN HEAD & NECK CANCER

  19. Slide 19: VCN-01 IV + Anti-PD-L1 Phase 1 Trial in HNSCC

    VCN-01 IV + ANTI-PD-L1 PHASE 1 TRIAL in HNSCC Multicenter, open-label, dose escalation study (NCT03799744) ✓ Single IV doses of VCN-01 combined with anti-PD-L1 ✓ Patients with metastatic squamous cell carcinoma of the head & neck previously REFRACTORY to anti-PD(L)1 treatment (R/M HNSCC) ✓ Evaluate

  20. Slide 20: Extended Survival with VCN-01 + Durvalumab

    EXTENDED SURVIVAL with VCN-01+DURVALUMAB Survival correlated with PD-L1 upregulation after VCN-01 treatment • Higher than expected survival (OS) Overall Survival vs CPS in Biopsies at Day 8 despite previous anti-PD(L)1 failure Spearman r = 0.7676 P (2-tailed) = 0.0050 Regimen Median OS (95% CI), mos

  21. Slide 21: VCN-01 Findings in R/M HNSCC

    VCN-01 FINDINGS in R/M HNSCC Data support VCN-01 MOA and immune enhancing effects • VCN-01 has an acceptable adverse event profile when administered prior to durvalumab (Imfinzi®) • VCN-01 reaches tumors, has sustained replication and PH20 expression • VCN-01 treatment led to downregulation of tumor

  22. Slide 22: VCN-01 in Retinoblastoma

    @ Theriva VCN-01 IN RETINOBLASTOMA

  23. Slide 23: Retinoblastoma, a Rare Pediatric Malignancy

    RETINOBLASTOMA, A RARE PEDIATRIC MALIGNANCY • Retinoblastoma (Rb) is an orphan indication that accounts for ~2-3% of all childhood cancers¹ • 200-300 cases each year in the USA, EU²-⁴ • VCN-01 selectivity enables development as an intravitreal treatment for Rb patients • VCN-01 could be used in comb

  24. Slide 24: VCN-01 in Retinoblastoma

    VCN-01 IN RETINOBLASTOMA • Single center, open-label, dose escalation study of intravitreal (IVit) VCN-01¹-³ Promising Results in Patients Treated • Children aged 1-12 years (n=9) with High Dose VCN-01 • Retinoblastoma that is recurrent or refractory to chemotherapy Reduced number and size of tumor

  25. Slide 25: Interim Adverse Event Data for Intravitreal VCN-01

    INTERIM ADVERSE EVENT DATA FOR INTRAVITREAL VCN-01 Two Intravitreal VCN-01 Doses of 2.0x10⁹ or 2.0x1010 vp per eye¹ Adverse Reaction Pts All Grades Grade ≥3 Stable Electroretinographic Signals CTCAE grade N n % n % Uveitis 6 2 33% 2 33% Eye oedema 6 1 17% 0 0% Conjunctival hyperemia 6 1 17% 0 0% Eye

  26. Slide 26: VCN-01 Development in Retinoblastoma

    VCN-01 DEVELOPMENT IN RETINOBLASTOMA • Phase 1 ISS Completed H1 2024 • Initial data demonstrate acceptable adverse event profile and one durable complete response • Developing a clinical protocol for an open-label, multinational study • Retinoblastoma patients with vitreous seeds • IVit VCN-01 in co

  27. Slide 27: VCN-X Next Generation OV Discovery Platform

    VCN-X NEXT GENERATION OV DISCOVERY PLATFORM

  28. Slide 28: Albumin Shield to Enhance OV Systemic Delivery

    ALBUMIN SHIELD™ to ENHANCE OV SYSTEMIC DELIVERY • Albumin Shield technology protects OVs as they OV Parent oncolytic virus (OV) susceptible to neutralizing travel to tumors after systemic administration¹,² antibodies • Albumin Shield modified OVs bind albumin in the patient’s blood to form a protect

  29. Slide 29: Theriva OV Pipeline Discovery and Development

    THERIVA OV PIPELINE DISCOVERY AND DEVELOPMENT Advancing founders’ decade of world leading OV innovation Common Features Product Specific Features Clinically-tested Adenovirus Expressing PH20 VCN-11 Hyaluronidase alone Hyaluronidase to Degrade Stroma + VCN-12 Hyaluronidase + Toxins Albumin Shield™ To

  30. Slide 30: Appendices

    @ Theriva APPENDICES

  31. Slide 31: Intellectual Property

    INTELLECTUAL PROPERTY Hyaluronidase OV Albumin Shield™ Oral β-Lactamase Oral IAP VCN-01, VCN-11 VCN-11, Discovery SYN-004, -006, -007 SYN-020 Composition of Matter Composition of Matter Composition of Matter Manufacturing Know-how (exp 2030) (exp 2034) (exp 2031-5) (Trade Secret) Methods of Use and

  32. Slide 32: VCN-01 in Pancreatic Cancer

    @ Theriva VCN-01 IN PANCREATIC CANCER

  33. Slide 33: VCN Oncolytic Virus Genetic Modifications

    VCN ONCOLYTIC VIRUS GENETIC MODIFICATIONS Fiber Shaft KKTK Ad5 ABD albumin binding domain LITR E1a MLP L1 L2 L3 L4 L5 RITR (streptococcal protein G)¹ wild type | | Ad5 Adenovirus type 5 Enables replication in normal cells Facilitates liver sequestration E1a-Δ24 deletion of 24 base pairs within the E

  34. Slide 34: Extensive VCN-01 Phase 1 Clinical Experience

    EXTENSIVE VCN-01 PHASE 1 CLINICAL EXPERIENCE 89 Patients Treated in Diverse Cancer Indications Phas Rout Location Indication Co-therapy Status Registry e e Multicenter (ESP) 1 Part I: None Part I: Solid tumor Parts II,III: Gemcitabine + IV Complete¹ NCT02045602 Part II, III: PDAC nab-Paclitaxel Gemc

  35. Slide 35: Most Common IV VCN-01 Related AEs

    MOST COMMON IV VCN-01 RELATED AEs [NCT02045602] ADVERSE EVENTS¹ Part I (Alone, n=16) Part II (Concomitant, 12)² Part III (Sequential, 14)³ Grade 1-2 Grade ≥3 Grade 1-2 Grade ≥3* Grade 1-2 Grade ≥3 Febrile neutropenia - - - 2 (16.7%) - - Neutropenia/Neutrophil count decreased 2 (12.5%) - 1 ( 8.3%) 1

  36. Slide 36: Expansion Opportunities for VCN-01 in PDAC

    EXPANSION OPPORTUNITIES for VCN-01 in PDAC Alternate treatment lines and new chemotherapy combinations Borderline Locally Advanced Metastatic / Recurrent Status Resectable Resectable (unresectable) (unresectable) Staging Stage I Stage II Stage III Stage IV Radiotherapy if increases resection margins

  37. Slide 37: VCN-01 with Gemcitabine/Nab Paclitaxel

    VCN-01 WITH GEMCITABINE/ NAB PACLITAXEL Potential survival benefit compared to all first-line chemotherapy COMPANY THERIVA BIOLOGICS (Phase 1) PDAC FIRST LINE CHEMOTHERAPY Virus VCN-01 VCN-01 .. .. .. 3.3x1012 vp x1 Dose 1x1013 vp x 1* .. .. .. .. 1x1013 vp x 1* Chemotherapy Gemcitabine + Gemcitabin

  38. Slide 38: Theriva Oncolytic Viruses Key Publications

    THERIVA ONCOLYTIC VIRUSES KEY PUBLICATIONS Bayo-Puxan N et al. (2006) Role of the putative heparan sulfate glycosaminoglycan-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob- mediated retargeting. J Gen Virol 87:2487–2495 Bazan-Peregrino M et al. (2021) VCN-01 disrupts

  39. Slide 39: Pancreatic Cancer References

    PANCREATIC CANCER REFERENCES DESCRIPTION, CLASSIFICATION, STAGING, STROMA Balachandran VP et al. (2019) Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology 156:2056-72 Christenson ES et al. (2020) Current and emerging therapies for patients wit

  40. Slide 40: Retinoblastoma (Rb) References

    RETINOBLASTOMA (Rb) REFERENCES DESCRIPTION, CLASSIFICATION, STAGING American Academy of Ophthalmology. EyeWiki®. Retinoblastoma. https://eyewiki.org/Retinoblastoma American Cancer Society. Key statistics for retinoblastoma. https://www.cancer.org/cancer/retinoblastoma/about/key-statistics.html Cantu

  41. Slide 41: OV Company References

    OV COMPANY REFERENCES CG Oncology CG0070 (cretostimogene grenadenorepvec) https://cgoncology.com Ramesh N et al. (2006) CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 12:305 Svatek R

  42. Slide 42: OV Company References

    OV COMPANY REFERENCES Oncolytics Biotech: Pelareorep (formerly Reolysin®) https://oncolyticsbiotech.com Arnold D et al. Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients – Results from the GOBLET study

Theriva Biologics — Investor Presentation (December 2024) on 6ix